India Pharma Outlook Team | Tuesday, 09 December 2025
Immutep has sealed a wide-reaching licensing pact with Dr Reddy’s Laboratories, giving the Indian drugmaker exclusive rights to develop and commercialize Eftilagimod Alfa (efti) across most global markets, except North America, Europe, Japan, and Greater China.
The agreement centers on advancing efti, a first-in-class immune activator now in the registrational Phase III TACTI-004 trial for first-line treatment of advanced or metastatic non-small cell lung cancer.
The therapy is also under investigation in head and neck cancer, breast cancer, and soft-tissue sarcoma, positioning it as a potential multi-cancer option. Under the deal, Immutep’s subsidiary Immutep SAS and Dr Reddy’s Laboratories SA will jointly push development forward. Immutep secures major long-term value through milestones and royalties while keeping control of manufacturing and preserving full commercial rights in high-value regions.
Also Read: How Emerging Biotech Startups Reshaping the Bioprocessing Future
"Its broad potential extends to other major cancers across multiple stages of disease. Through this agreement, we look forward to leveraging our expertise and strong market access to advance the development and commercialization of this promising cancer therapy in the licensed markets,” stated MV Ramana, CEO – Branded Markets (India & Emerging Markets), Dr Reddy’s.
“This agreement with Dr Reddy’s marks a significant milestone for Immutep and further validates the potential of efti. Dr Reddy’s proven capabilities and reach in the licensed markets make them an ideal partner to maximise the impact of our innovation and serve a large number of patients across the globe," said Marc Voigt, CEO of Immutep.
Dr Reddy’s will pay $20 million upfront, with the potential for up to $349.5 million in regulatory and commercial milestones, along with double-digit royalties on sales. The company sees efti as a therapy that could shift treatment standards when used with pembrolizumab and chemotherapy.
.jpg)
